JP Morgan Chase
AVDL

JP Morgan Chase’s Avadel Pharmaceuticals AVDL Stock Holding History

JP Morgan Chase’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-122,476
Closed -$2.64M – 7521
2025
Q4 		$2.64M Sell
122,476
-442,995
-78% -$8.6M ﹤0.01% 3869
2025
Q3 		$8.63M Buy
565,471
+453,582
+405% +$5.9M ﹤0.01% 2857
2025
Q2 		$990K Sell
111,889
-4,085
-4% -$35.9K ﹤0.01% 4384
2025
Q1 		$908K Buy
115,974
+4,762
+4% +$39.9K ﹤0.01% 4416
2024
Q4 		$1.17M Sell
111,212
-3,813
-3% -$46.3K ﹤0.01% 4527
2024
Q3 		$1.51M Buy
115,025
+2,259
+2% +$34.4K ﹤0.01% 4219
2024
Q2 		$1.59M Buy
112,766
+59,545
+112% +$971K ﹤0.01% 3966
2024
Q1 		$899K Buy
53,221
+5,018
+10% +$74.7K ﹤0.01% 4422
2023
Q4 		$681K Sell
48,203
-404,269
-89% -$4.75M ﹤0.01% 4584
2023
Q3 		$4.66M Buy
452,472
+119,848
+36% +$1.61M ﹤0.01% 2893
2023
Q2 		$5.48M Sell
332,624
-25,236
-7% -$328K ﹤0.01% 2786
2023
Q1 		$3.28M Buy
357,860
+333,397
+1,363% +$2.74M ﹤0.01% 3150
2022
Q4 		$176K Sell
24,463
-2,389
-9% -$16.8K ﹤0.01% 5104
2022
Q3 		$135K Buy
26,852
+1,993
+8% +$11K ﹤0.01% 5143
2022
Q2 		$60K Sell
24,859
-4,761
-16% -$19.5K ﹤0.01% 5602
2022
Q1 		$202K Buy
29,620
+1,758
+6% +$12.1K ﹤0.01% 5185
2021
Q4 		$225K Sell
27,862
-220,602
-89% -$2.02M ﹤0.01% 5284
2021
Q3 		$2.43M Buy
248,464
+40,605
+20% +$320K ﹤0.01% 3632
2021
Q2 		$1.4M Sell
207,859
-95,182
-31% -$756K ﹤0.01% 4051
2021
Q1 		$2.74M Sell
303,041
-159,016
-34% -$1.29M ﹤0.01% 3471
2020
Q4 		$3.09M Buy
462,057
+131,013
+40% +$819K ﹤0.01% 3175
2020
Q3 		$1.7M Sell
331,044
-18,178
-5% -$132K ﹤0.01% 3341
2020
Q2 		$2.82M Buy
349,222
+326,522
+1,438% +$2.88M ﹤0.01% 2874
2020
Q1 		$180K Hold
22,700
– – ﹤0.01% 4311
2019
Q4 		$171K Hold
22,700
– – ﹤0.01% 4732
2019
Q3 		$94K Hold
22,700
– – ﹤0.01% 4923
2019
Q2 		$64K Buy
22,700
+18,000
+383% +$30.9K ﹤0.01% 5082
2019
Q1 		$7K Hold
4,700
– – ﹤0.01% 5578
2018
Q4 		$12K Hold
4,700
– – ﹤0.01% 5407
2018
Q3 		$21K Sell
4,700
-131,173
-97% -$708K ﹤0.01% 5409
2018
Q2 		$833K Buy
+135,873
New +$953K ﹤0.01% 3930
2018
Q1 		– Sell
-1,773
Closed -$15K – 5375
2017
Q4 		$15K Sell
1,773
-30,650
-95% -$287K ﹤0.01% 5200
2017
Q3 		$329K Sell
32,423
-34,012
-51% -$325K ﹤0.01% 3956
2017
Q2 		$733K Buy
+66,435
New +$667K ﹤0.01% 3569
2017
Q1 		– Sell
-660
Closed -$7K – 5035
2016
Q4 		$7K Buy
660
+626
+1,841% +$6.88K ﹤0.01% 4832
2016
Q3 		$0 Sell
34
-84
-71% -$1.1K ﹤0.01% 4532
2016
Q2 		$1K Sell
118
-316,874
-100% -$3.38M ﹤0.01% 4657
2016
Q1 		$3.5M Buy
316,992
+30,760
+11% +$306K ﹤0.01% 2409
2015
Q4 		$3.5M Buy
286,232
+10,992
+4% +$171K ﹤0.01% 2443
2015
Q3 		$4.49M Buy
+275,240
New +$6.06M ﹤0.01% 2286
2014
Q4 		– Sell
-1,275,916
Closed -$18.3M – 4217
2014
Q3 		$18.3M Sell
1,275,916
-55,900
-4% -$803K ﹤0.01% 1501
2014
Q2 		$20M Sell
1,331,816
-182,683
-12% -$2.2M 0.01% 1355
2014
Q1 		$20.3M Buy
+1,514,499
New +$16.2M 0.01% 1304

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

JP Morgan Chase's AVDL Position: Q1 2026 in Review

JP Morgan Chase sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 122,476 shares — an estimated $2.64M sold.

JP Morgan Chase first reported a position in AVDL in Q1 2014 and held it in 43 quarters. The position peaked at $20.3M in Q1 2014. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • JP Morgan Chase reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • JP Morgan Chase sold 122,476 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.64M.
  • JP Morgan Chase first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 43 quarters.
  • JP Morgan Chase's Avadel Pharmaceuticals position peaked at $20.3M in Q1 2014.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.